As of 2025-09-18, the EV/EBITDA ratio of Urogen Pharma Ltd (URGN) is -6.07. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. URGN's latest enterprise value is 870.65 mil USD. URGN's TTM EBITDA according to its financial statements is -143.37 mil USD. Dividing these 2 quantities gives us the above URGN EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.3x - 10.4x | 10.4x |
| Forward P/E multiples | 8.9x - 11.6x | 11.1x |
| Fair Price | (28.24) - (32.95) | (34.04) |
| Upside | -256.0% - -282.1% | -288.1% |
| Date | EV/EBITDA |
| 2025-09-17 | -6.07 |
| 2025-09-16 | -6.06 |
| 2025-09-15 | -6.06 |
| 2025-09-12 | -6.30 |
| 2025-09-11 | -6.44 |
| 2025-09-10 | -6.40 |
| 2025-09-09 | -6.91 |
| 2025-09-08 | -7.14 |
| 2025-09-05 | -6.32 |
| 2025-09-04 | -6.30 |
| 2025-09-03 | -6.48 |
| 2025-09-02 | -6.53 |
| 2025-08-29 | -6.51 |
| 2025-08-28 | -6.44 |
| 2025-08-27 | -6.54 |
| 2025-08-26 | -6.52 |
| 2025-08-25 | -6.20 |
| 2025-08-22 | -6.51 |
| 2025-08-21 | -6.61 |
| 2025-08-20 | -6.46 |
| 2025-08-19 | -6.34 |
| 2025-08-18 | -6.49 |
| 2025-08-15 | -6.59 |
| 2025-08-14 | -6.71 |
| 2025-08-13 | -6.72 |
| 2025-08-12 | -6.43 |
| 2025-08-11 | -6.12 |
| 2025-08-08 | -5.96 |
| 2025-08-07 | -6.23 |
| 2025-08-06 | -6.69 |
| 2025-08-05 | -6.92 |
| 2025-08-04 | -6.65 |
| 2025-08-01 | -6.49 |
| 2025-07-31 | -6.38 |
| 2025-07-30 | -6.43 |
| 2025-07-29 | -6.33 |
| 2025-07-28 | -6.33 |
| 2025-07-25 | -6.35 |
| 2025-07-24 | -6.04 |
| 2025-07-23 | -6.25 |
| 2025-07-22 | -5.70 |
| 2025-07-21 | -5.22 |
| 2025-07-18 | -5.16 |
| 2025-07-17 | -5.20 |
| 2025-07-16 | -4.86 |
| 2025-07-15 | -4.76 |
| 2025-07-14 | -4.91 |
| 2025-07-11 | -4.83 |
| 2025-07-10 | -4.96 |
| 2025-07-09 | -4.69 |